Tumor News and Research

RSS

Digital versions of standard molecular biology tool to detect common tumor-associated mutation in CSF

Massachusetts General Hospital (MGH) researchers and their colleagues have used digital versions of a standard molecular biology tool to detect a common tumor-associated mutation in the cerebrospinal fluid (CSF) of patients with brain tumors. In their report being published in the open-access journal Molecular Therapy - Nucleic Acids, the investigators describe using advanced forms of the gene-amplification technology polymerase chain reaction (PCR) to analyze bits of RNA carried in membrane-covered sacs called extracellular vesicles for the presence of a tumor-associated mutation in a gene called IDH1.

24 Jul 2013

NF-κB protein complex may boost immune system to eliminate cancerous cells

Researchers at Moffitt Cancer Center and Tianjin Medical University Cancer Institute and Hospital in China have discovered a gene expression signature that may lead to new immune therapies for lung cancer patients.

23 Jul 2013

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer.

22 Jul 2013

Cedars-Sinai investigator awarded grant to study cell metabolism in childhood sarcomas

Sandra Orsulic, PhD, director of Women's Cancer Biology in the Women's Cancer Program at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, was awarded a $250,000 grant from Alex's Lemonade Stand Foundation to study cell metabolism in childhood sarcomas.

22 Jul 2013

New stem cell discovery may help scientists replace damaged organs

Stem-cell researchers at UC San Francisco have found a key role for a protein called BMI1 that may help scientists direct the development of tissues to replace damaged organs in the human body.

22 Jul 2013

Absence of Shp-2 enzyme near cartilage cells can lead to multiple benign cartilage tumors in mice

Rhode Island Hospital researchers have found that the absence of the Shp-2 enzyme near specialized cartilage cells can lead to the development of multiple benign cartilage tumors in mice, a model that recapitulates the rare human tumor syndrome metachondromatosis.

20 Jul 2013

Researchers identify mechanism behind pediatric solid tumors

Most of the time, it takes decades of accumulating genetic errors for a tumor to develop. While this explains the general occurrence of cancer in adults, it leaves a gap in understanding of the cause of pediatric tumors.

20 Jul 2013

Mirror Effect of Immunovative Therapies: A new approach to cancer treatment

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd, a biotech company in Israel, describes a new and unique approach to cancer treatment.

20 Jul 2013

UCSF researchers find a way to knock down cancers caused by tumor-driving protein

UC San Francisco researchers have found a way to knock down cancers caused by a tumor-driving protein called -myc,- paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.

20 Jul 2013

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

A phase 2 EORTC trial for patients with inoperable desmoid-type fibromatosis has shown that moderate dose radiotherapy is an effective treatment for patients with such a rare type of tumor. The study results published in Annals of Oncology show that response after radiation therapy is slow, and that continuing regression is seen even after three years.

19 Jul 2013

NCI awards $1.5M grant to LSUHSC researcher to study role of chronic inflammation in cancer

Yan Cui, PhD, Associate Professor of Microbiology, Immunology, & Parasitology at LSU Health Sciences Center New Orleans and the LSUHSC Stanley S. Scott Cancer Center, has been awarded a $1.5 million grant over five years by the National Cancer Institute to study the role of chronic inflammation in the development and progression of cancer.

19 Jul 2013

UCSF researchers find way to knock down cancers caused by myc protein

UC San Francisco researchers have found a way to knock down cancers caused by a tumor-driving protein called "myc," paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.

19 Jul 2013

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

19 Jul 2013

Researchers develop new drug delivery technique for diabetes treatment

Researchers have developed a drug delivery technique for diabetes treatment in which a sponge-like material surrounds an insulin core. The sponge expands and contracts in response to blood sugar levels to release insulin as needed. The technique could also be used for targeted drug delivery to cancer cells.

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Oncodesign receives AAALAC certification for Dijon-based research center

Oncodesign, a contract research laboratory for the discovery of new anticancer therapies, today announces that its Dijon-based research center has received AAALAC certification.

18 Jul 2013

Both milky spots and fat cells in omentum promote ovarian cancer metastases

Cancer researchers have wondered why ovarian cancer cells are so attracted to the abdominal cavity, especially the omentum, with the hope that such an understanding could lead to better disease management or even prevention.

18 Jul 2013

Breast cancer pilot study: Patients benefit from treatments guided by molecular profiling

The Side-Out Foundation's breast cancer pilot study, led by the Translational Genomics Research Institute, Translational Drug Development and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling.

18 Jul 2013

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems.

17 Jul 2013

Tumor News and Research

Digital versions of standard molecular biology tool to detect common tumor-associated mutation in CSF

NF-κB protein complex may boost immune system to eliminate cancerous cells

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

Cedars-Sinai investigator awarded grant to study cell metabolism in childhood sarcomas

New stem cell discovery may help scientists replace damaged organs

Absence of Shp-2 enzyme near cartilage cells can lead to multiple benign cartilage tumors in mice

Researchers identify mechanism behind pediatric solid tumors

Mirror Effect of Immunovative Therapies: A new approach to cancer treatment

UCSF researchers find a way to knock down cancers caused by tumor-driving protein

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

NCI awards $1.5M grant to LSUHSC researcher to study role of chronic inflammation in cancer

UCSF researchers find way to knock down cancers caused by myc protein

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

Researchers develop new drug delivery technique for diabetes treatment

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Oncodesign receives AAALAC certification for Dijon-based research center

Both milky spots and fat cells in omentum promote ovarian cancer metastases

Breast cancer pilot study: Patients benefit from treatments guided by molecular profiling

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News